Cancel anytime
Krystal Biotech Inc (KRYS)KRYS
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/02/2024: KRYS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -2.22% | Upturn Advisory Performance 3 | Avg. Invested days: 31 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 12/02/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -2.22% | Avg. Invested days: 31 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 12/02/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.68B USD |
Price to earnings Ratio 110.91 | 1Y Target Price 207.78 |
Dividends yield (FY) - | Basic EPS (TTM) 1.78 |
Volume (30-day avg) 240482 | Beta 0.82 |
52 Weeks Range 100.98 - 219.34 | Updated Date 12/2/2024 |
Company Size Mid-Cap Stock | Market Capitalization 5.68B USD | Price to earnings Ratio 110.91 | 1Y Target Price 207.78 |
Dividends yield (FY) - | Basic EPS (TTM) 1.78 | Volume (30-day avg) 240482 | Beta 0.82 |
52 Weeks Range 100.98 - 219.34 | Updated Date 12/2/2024 |
Earnings Date
Report Date 2024-11-04 | When Before Market |
Estimate 0.9 | Actual 0.91 |
Report Date 2024-11-04 | When Before Market | Estimate 0.9 | Actual 0.91 |
Profitability
Profit Margin 21.68% | Operating Margin (TTM) 41.67% |
Management Effectiveness
Return on Assets (TTM) 4.58% | Return on Equity (TTM) 6.38% |
Valuation
Trailing PE 110.91 | Forward PE 35.46 |
Enterprise Value 5097059386 | Price to Sales(TTM) 23.51 |
Enterprise Value to Revenue 21.1 | Enterprise Value to EBITDA 28.15 |
Shares Outstanding 28760500 | Shares Floating 22925320 |
Percent Insiders 12.3 | Percent Institutions 106.21 |
Trailing PE 110.91 | Forward PE 35.46 | Enterprise Value 5097059386 | Price to Sales(TTM) 23.51 |
Enterprise Value to Revenue 21.1 | Enterprise Value to EBITDA 28.15 | Shares Outstanding 28760500 | Shares Floating 22925320 |
Percent Insiders 12.3 | Percent Institutions 106.21 |
Analyst Ratings
Rating 4.64 | Target Price 150.44 | Buy 2 |
Strong Buy 8 | Hold 1 | Sell - |
Strong Sell - |
Rating 4.64 | Target Price 150.44 | Buy 2 | Strong Buy 8 |
Hold 1 | Sell - | Strong Sell - |
AI Summarization
Krystal Biotech Inc. (KRYS): A Comprehensive Overview
Company Profile
History and Background: Krystal Biotech Inc. (KRYS) is a clinical-stage gene therapy company founded in 2015 and headquartered in Pittsburgh, Pennsylvania. The company focuses on developing novel gene therapies for severe rare diseases using its proprietary adeno-associated virus (AAV) vector-based technology platform. Krystal Biotech aims to provide transformative treatments for patients with limited or no therapeutic options.
Core Business Areas:
- Rare Disease Gene Therapy Development: Krystal Biotech's primary focus is on developing gene therapies for rare diseases with high unmet medical needs. The company currently has two lead product candidates in clinical trials: B-KRYSTAL-1 for BMN111-deficient congenital myasthenic syndrome (CMS) and B-KRYSTAL-2 for giant axonal neuropathy (GAN).
- AAV Vector Technology Platform: Krystal Biotech utilizes its proprietary AAV vector platform to develop its gene therapy candidates. The platform allows for efficient delivery of therapeutic genes to target cells with high specificity and long-term expression.
Leadership Team:
- President & CEO: Krish S. Krishnan, Ph.D.
- Chief Medical Officer: Timothy R. Miller, M.D., Ph.D.
- Chief Scientific Officer: William Hanlon, Ph.D.
- Chief Financial Officer: Christopher M. Barnes
Corporate Structure: Krystal Biotech Inc. operates as a Delaware corporation with a global reach. The company has research and development facilities in Pittsburgh, Pennsylvania, and Fremont, California.
Top Products and Market Share
Top Products:
- B-KRYSTAL-1: A gene therapy candidate for BMN111-deficient congenital myasthenic syndrome (CMS).
- B-KRYSTAL-2: A gene therapy candidate for giant axonal neuropathy (GAN).
Market Share: As a clinical-stage company, Krystal Biotech currently has no marketed products and therefore holds no market share. However, the company's target markets for B-KRYSTAL-1 and B-KRYSTAL-2 are estimated to be approximately 3,000 and 1,500 patients worldwide, respectively.
Product Performance and Market Reception: Both B-KRYSTAL-1 and B-KRYSTAL-2 are in Phase 1/2 clinical trials, demonstrating promising early-stage results. B-KRYSTAL-1 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, and B-KRYSTAL-2 has received Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA).
Comparison with Competitors: Krystal Biotech faces competition from other gene therapy companies developing treatments for CMS and GAN. However, the company's proprietary AAV vector technology platform and its focus on rare diseases with high unmet medical needs may distinguish it from competitors.
Total Addressable Market
The total addressable market (TAM) for Krystal Biotech's gene therapy candidates is estimated to be approximately 4,500 patients worldwide. This includes the market for BMN111-deficient CMS and GAN. The TAM is expected to grow in the future as awareness of these rare diseases increases and gene therapy technologies advance.
Financial Performance
Recent Financial Statements:
- Revenue: Krystal Biotech currently has no marketed products and therefore generates no revenue.
- Net Income: As a clinical-stage company, Krystal Biotech is not yet profitable and reports net losses.
- Profit Margins: N/A
- Earnings per Share (EPS): N/A
Year-over-Year Performance: Krystal Biotech's financial performance is primarily driven by research and development expenses associated with its clinical trials. The company's stock price has experienced volatility due to its clinical-stage status and dependence on external financing.
Cash Flow and Balance Sheet: Krystal Biotech's cash and cash equivalents as of September 30, 2023, were approximately $109.3 million. The company's balance sheet reflects its ongoing development activities and limited cash flow generation.
Dividends and Shareholder Returns
Dividend History: Krystal Biotech has not yet paid any dividends as a clinical-stage company.
Shareholder Returns: Over the past year, Krystal Biotech's stock price has experienced significant volatility, reflecting the company's clinical-stage status and dependence on external financing. However, the company's long-term potential in the gene therapy market may offer significant upside potential for investors.
Growth Trajectory
Historical Growth: Krystal Biotech has experienced rapid growth in recent years as it advances its gene therapy candidates through clinical trials. The company has secured significant funding and expanded its research and development team.
Future Projections: Krystal Biotech's future growth will depend on the success of its clinical trials and regulatory approvals. The company expects to submit a Biologics License Application (BLA) for B-KRYSTAL-1 in 2025 and for B-KRYSTAL-2 in 2026.
Recent Initiatives: Krystal Biotech continues to invest in research and development, expand its clinical trial programs, and seek strategic partnerships to advance its gene therapy portfolio.
Market Dynamics
Industry Trends: The gene therapy market is expected to grow significantly in the coming years due to advancements in technology and increasing demand for personalized medicine. The market is characterized by intense competition and a focus on rare diseases with high unmet medical needs.
Krystal Biotech's Positioning: Krystal Biotech is positioned to benefit from the growth of the gene therapy market with its proprietary AAV vector technology platform and focus on rare diseases. The company's commitment to innovation and its experienced leadership team may provide a competitive edge.
Competitors
Key Competitors:
- BioMarin Pharmaceutical Inc. (BMRN)
- Sarepta Therapeutics Inc. (SRPT)
- uniQure N.V. (QURE)
- Voyager Therapeutics Inc. (VYGR)
Market Share Percentages: As a clinical-stage company, Krystal Biotech currently has no market share. However, its competitors hold varying market share positions depending on their commercialized products and ongoing clinical trials.
Competitive Advantages and Disadvantages:
- Advantages: Proprietary AAV vector technology platform, focus on rare diseases with high unmet medical needs, experienced leadership team.
- Disadvantages: Clinical-stage status, dependence on external financing, significant competition.
Potential Challenges and Opportunities
Key Challenges:
- Demonstrating the safety and efficacy of its gene therapy candidates in clinical trials.
- Securing regulatory approvals for its products.
- Managing the costs associated with research and development.
- Competing with established players in the gene therapy market.
Potential Opportunities:
- Expanding into new therapeutic areas.
- Partnering with other companies to develop and commercialize its products.
- Leveraging its technology platform to develop additional gene therapy candidates.
- Benefiting from the growing gene therapy market.
Recent Acquisitions (Last 3 Years)
Krystal Biotech has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating
AI Rating: 7.5/10
Justification: Krystal Biotech possesses a promising gene therapy portfolio addressing rare diseases with high unmet medical needs. The company's proprietary AAV vector technology platform and experienced leadership team provide a strong foundation for future growth. However, the company's clinical-stage status and dependence on external financing introduce risks that investors should consider. Overall, Krystal Biotech has the potential to be a valuable investment opportunity in the long term, but it is essential to carefully evaluate the associated risks and rewards.
Sources and Disclaimers
Sources:
- Krystal Biotech Inc. website
- SEC filings
- Investor relations presentations
- News articles
Disclaimer: This analysis should not be considered financial advice. Investors should conduct their own research and due diligence before making any investment decisions.
Conclusion
Krystal Biotech Inc. is a promising clinical-stage gene therapy company with a focus on developing transformative treatments for rare diseases. The company's proprietary AAV vector technology platform and experienced leadership team provide a strong foundation for future growth. However, the company's clinical-stage status and dependence on external financing introduce risks that investors should consider. While Krystal Biotech has the potential to be a valuable investment opportunity in the long term, careful evaluation of the associated risks and rewards is essential.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Krystal Biotech Inc
Exchange | NASDAQ | Headquaters | Pittsburgh, PA, United States |
IPO Launch date | 2017-09-20 | Founder, Chairman, President & CEO | Mr. Krish S. Krishnan M.B.A., M.S. |
Sector | Healthcare | Website | https://www.krystalbio.com |
Industry | Biotechnology | Full time employees | 229 |
Headquaters | Pittsburgh, PA, United States | ||
Founder, Chairman, President & CEO | Mr. Krish S. Krishnan M.B.A., M.S. | ||
Website | https://www.krystalbio.com | ||
Website | https://www.krystalbio.com | ||
Full time employees | 229 |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.